Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma.

Hayes MP, Douglas W, Ellenson LH.

Gynecol Oncol. 2009 Jun;113(3):370-3. doi: 10.1016/j.ygyno.2008.12.021. Epub 2009 Mar 9.

2.

Molecular alterations in uterine serous carcinoma.

Hayes MP, Ellenson LH.

Gynecol Oncol. 2010 Feb;116(2):286-9. doi: 10.1016/j.ygyno.2009.11.012. Review.

PMID:
20109727
3.

Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.

Black JD, English DP, Roque DM, Santin AD.

Womens Health (Lond). 2014 Jan;10(1):45-57. doi: 10.2217/whe.13.72. Review.

4.

Early stage uterine serous carcinoma: management updates and genomic advances.

Fader AN, Santin AD, Gehrig PA.

Gynecol Oncol. 2013 Apr;129(1):244-50. doi: 10.1016/j.ygyno.2013.01.004. Epub 2013 Jan 12. Review.

PMID:
23321062
5.

Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.

Gadgeel SM, Wozniak A.

Clin Lung Cancer. 2013 Jul;14(4):322-32. doi: 10.1016/j.cllc.2012.12.001. Epub 2013 Jan 16. Review.

PMID:
23332287
6.

PIK3CA in Colorectal Cancer.

Cathomas G.

Front Oncol. 2014 Mar 3;4:35. doi: 10.3389/fonc.2014.00035. eCollection 2014. Review.

7.

High-content analysis of cancer genome DNA alterations.

Degenhardt YY, Wooster R, McCombie RW, Lucito R, Powers S.

Curr Opin Genet Dev. 2008 Feb;18(1):68-72. doi: 10.1016/j.gde.2008.01.005. Epub 2008 Mar 12. Review.

Supplemental Content

Support Center